...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Need An Explanation


"I think Zenith's uncommunicative management owes us an explanation of why nearly 40% of the company is now owned by Dart. Why did they allow ownership in Zenith to become so very concentrated?

The fact that you say you were offered shares suggests that an attempt to do a broader financing failed. That suggests they were fortunate that KD was willing to do it.

"What is that money being used for? What future needs for cash will they have?

Ongoing operations and they will need a decent cash position to do an RTO (assuming one is coming).

"Why are shares still being sold for a buck? What is the plan to increase the valuation of Zenith?

Each financing is a dilution. Each time they do it at $1.00 US, it's increased valuation. The only way it will increase is through an RTO/IPO and public trading, or positive efficacy data.

Share
New Message
Please login to post a reply